regulation of nuclear pre-mRNA domain containing 1AGenealiases: HsT3101 · P15RS
Q-omics provides the consensus-scored RPRD1A profile across patient tissues and cancer cell-line models. RPRD1A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, RPRD1A is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, RPRD1A RNA expression shows 21,002 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight OV, LIHC, and ACC as cancer lineages where RPRD1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPRD1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPRD1A survival associations across molecular data types. RPRD1A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPRD1A RNA expression–survival associations across cancer types. High RPRD1A expression shows unfavorable associations in LIHC, UVM and MESO, but favorable associations in OV, KIRC and LGG. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify OV as the clearest survival context for RPRD1A RNA expression.
This table summarizes RPRD1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for RPRD1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPRD1A shows lower tumor expression in KIRC and KICH and higher tumor expression in LIHC, HNSC, CHOL and THCA. The LIHC box plot shows higher RPRD1A RNA expression in tumor versus normal tissue (log2 FC = +1.020, t-test p < 0.001).
This table shows molecular features associated with RPRD1A in patient tissues and cancer cell lines. In patient samples, RPRD1A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPRD1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
